BR112021021632A8 - Terapia de gene de combinação intratecal e intravenosa para o tratamento da doença de batten infantil - Google Patents
Terapia de gene de combinação intratecal e intravenosa para o tratamento da doença de batten infantilInfo
- Publication number
- BR112021021632A8 BR112021021632A8 BR112021021632A BR112021021632A BR112021021632A8 BR 112021021632 A8 BR112021021632 A8 BR 112021021632A8 BR 112021021632 A BR112021021632 A BR 112021021632A BR 112021021632 A BR112021021632 A BR 112021021632A BR 112021021632 A8 BR112021021632 A8 BR 112021021632A8
- Authority
- BR
- Brazil
- Prior art keywords
- polynucleotide
- intrathecal
- treatment
- gene therapy
- batten disease
- Prior art date
Links
- 238000007913 intrathecal administration Methods 0.000 title abstract 3
- 238000001990 intravenous administration Methods 0.000 title abstract 3
- 208000031277 Amaurotic familial idiocy Diseases 0.000 title abstract 2
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 title abstract 2
- 238000001415 gene therapy Methods 0.000 title abstract 2
- 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 title abstract 2
- 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 title abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 7
- 108091033319 polynucleotide Proteins 0.000 abstract 7
- 239000002157 polynucleotide Substances 0.000 abstract 7
- 108700026244 Open Reading Frames Proteins 0.000 abstract 3
- 230000000295 complement effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000005260 human cell Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
TERAPIA DE GENE DE COMBINAÇÃO INTRATECAL E INTRAVENOSA PARA O TRATAMENTO DA DOENÇA DE BATTEN INFANTIL. A presente invenção refere-se a métodos para tratar IBD ou um distúrbio relacionado com IBD em um indivíduo em necessidade do mesmo, que compreendem administração intratecal combinada de um polinucleotídeo compreendendo uma fase de leitura aberta CLN1 e administração intravenosa do polinucleotídeo. O polinucleotídeo compreendendo a fase de leitura aberta CLN1 é um polinucleotídeo CLN1 tipo selvagem. Em outro aspecto, o polinucleotídeo compreendendo a fase de leitura aberta CLN1 compreende sequência polinucleotídica otimizada por códon do polinucleotídeo ou seu complemento e é otimizada por códon para expressão em uma célula humana.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962840360P | 2019-04-29 | 2019-04-29 | |
PCT/US2020/030427 WO2020223322A1 (en) | 2019-04-29 | 2020-04-29 | Intrathecal and intravenous combination gene therapy for the treatment of infantile batten disease |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112021021632A2 BR112021021632A2 (pt) | 2021-12-21 |
BR112021021632A8 true BR112021021632A8 (pt) | 2022-06-28 |
Family
ID=73029200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021021632A BR112021021632A8 (pt) | 2019-04-29 | 2020-04-29 | Terapia de gene de combinação intratecal e intravenosa para o tratamento da doença de batten infantil |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220193268A1 (pt) |
EP (1) | EP3963081A4 (pt) |
JP (1) | JP2022530264A (pt) |
KR (1) | KR20220046513A (pt) |
CN (1) | CN114269935A (pt) |
AU (1) | AU2020264438A1 (pt) |
BR (1) | BR112021021632A8 (pt) |
CA (1) | CA3138274A1 (pt) |
IL (1) | IL287608A (pt) |
MX (1) | MX2021013275A (pt) |
SG (1) | SG11202111908XA (pt) |
WO (1) | WO2020223322A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024011115A1 (en) * | 2022-07-06 | 2024-01-11 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus delivery of cln1 polynucleotide |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI688395B (zh) * | 2010-03-23 | 2020-03-21 | 英翠克頌公司 | 條件性表現治療性蛋白質之載體、包含該載體之宿主細胞及彼等之用途 |
AU2017284198B2 (en) * | 2016-06-13 | 2023-09-28 | The University Of North Carolina At Chapel Hill | Optimized CLN1 genes and expression cassettes and their use |
-
2020
- 2020-04-29 CN CN202080047719.4A patent/CN114269935A/zh active Pending
- 2020-04-29 US US17/607,315 patent/US20220193268A1/en active Pending
- 2020-04-29 KR KR1020217038864A patent/KR20220046513A/ko unknown
- 2020-04-29 MX MX2021013275A patent/MX2021013275A/es unknown
- 2020-04-29 SG SG11202111908XA patent/SG11202111908XA/en unknown
- 2020-04-29 WO PCT/US2020/030427 patent/WO2020223322A1/en unknown
- 2020-04-29 AU AU2020264438A patent/AU2020264438A1/en active Pending
- 2020-04-29 JP JP2021564486A patent/JP2022530264A/ja active Pending
- 2020-04-29 CA CA3138274A patent/CA3138274A1/en not_active Abandoned
- 2020-04-29 EP EP20798198.6A patent/EP3963081A4/en active Pending
- 2020-04-29 BR BR112021021632A patent/BR112021021632A8/pt not_active Application Discontinuation
-
2021
- 2021-10-27 IL IL287608A patent/IL287608A/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2022530264A (ja) | 2022-06-28 |
EP3963081A4 (en) | 2023-07-26 |
SG11202111908XA (en) | 2021-11-29 |
CA3138274A1 (en) | 2020-11-05 |
US20220193268A1 (en) | 2022-06-23 |
EP3963081A1 (en) | 2022-03-09 |
WO2020223322A1 (en) | 2020-11-05 |
AU2020264438A1 (en) | 2021-12-16 |
BR112021021632A2 (pt) | 2021-12-21 |
CN114269935A (zh) | 2022-04-01 |
KR20220046513A (ko) | 2022-04-14 |
MX2021013275A (es) | 2022-03-17 |
IL287608A (en) | 2021-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Baum et al. | Injection of botulinum toxin for preventing salivary gland toxicity after PSMA radioligand therapy: an empirical proof of a promising concept | |
BR112018016001A2 (pt) | composição farmacêutica, métodos de tratamento e usos da mesma | |
BR112018008971A2 (pt) | materiais e métodos para tratamento de doença de armazenamento de glicogênio tipo 1a | |
BR112015017858A2 (pt) | sistemas e métodos para suporte de decisão clínica | |
CY1119295T1 (el) | Γονιδιακη θεραπεια για ασθενειες λυσοσωμικης αποθhκευσης | |
BR112018075692A2 (pt) | genes cln1 otimizados e cassetes de expressão e seu uso | |
BR112014027571A2 (pt) | métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas | |
BR112015028340A2 (pt) | Composições farmacêuticas envolvendo agente terapêutico baseado em hemoglobina modificada para direcionamento e tratamento de câncer e diagnóstico por imagem e um método para o preparo do agente terapêutico | |
BR112021021632A8 (pt) | Terapia de gene de combinação intratecal e intravenosa para o tratamento da doença de batten infantil | |
CL2023001351A1 (es) | Métodos de tratamiento de la insuficiencia cardíaca mediante la administración de omecamtiv mecarbil. | |
BR112019008384A2 (pt) | composição farmacêutica, processos para tratamento e seus usos | |
TR201902073T4 (tr) | Bir atenüe Newcastle hastalığı virüsü sağlayan bileşimler ve neoplaziyi tedavi etmek için kullanım yöntemleri. | |
BR112014018485A8 (pt) | Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf | |
MA40057A (fr) | Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants | |
BR112022020277A2 (pt) | Vacina anticâncer terapêutica individualizada, métodos para preparar a vacina anticâncer terapêutica individualizada e para tratar um paciente com câncer, polinucleotídeo, vetor, célula hospedeira, polipeptídeo codificado, e, proteína dimérica | |
BR112017009552A8 (pt) | Métodos para alvejar o controle transcricional em regiões de super-realçador | |
BR112014001170A2 (pt) | cateter, especialmente um cateter permanente, para tratamento de problemas funcionais e/ou doenças da bexiga e/ou próstata | |
EA201790352A1 (ru) | Терапевтическое лечение на основе анаморелина | |
BR112018017247A2 (pt) | ?polinucleotídeo, vetor de ácido nucleico, preparação farmacêutica, kit, e, métodos para fabricar um vetor viral adenoassociado recombinante e para tratar uma doença? | |
BR112022021468A2 (pt) | Genes gla otimizados por códon e usos dos mesmos | |
BR112014002407A2 (pt) | método para melhorar a terapia contra doenças autoimunes tais como artrite reumatóide | |
BR112022008321A2 (pt) | Polipeptídeos isolados, polipeptídeo, ácido nucleico isolado, vetor de expressão, célula hospedeira, métodos para produzir um polipeptídeo, para tratar câncer, para tratar uma doença neurológica ou neurodegenerativa, para repolarizar células supressoras, para repolarizar macrófagos de tumor e para ativar células mieloides em um sujeito e composições farmacêuticas | |
BR112018006572A2 (pt) | terapia de combinação racional para o tratamento de câncer | |
WO2013106766A3 (en) | THERAPEUTIC INDICATIONS OF miR-1291 | |
CO2022006772A2 (es) | Composiciones y métodos para el tratamiento de los trastornos de almacenamiento de glucógeno |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) ; ABEONA THERAPEUTICS, INC. (US) |
|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |